3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
3
Thoracic
1
Genitourinary
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
2
Carcinoma, Renal Cell
2
Urothelial Cancer
1
Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
20
atezolizumab
8
Nivolumab
8
Docetaxel
7
Carboplatin
6
cemiplimab
5
Immune Checkpoint Inhibitors
5
Radiotherapy
4
Paclitaxel
4
Filgrastim
4
Drug Therapy
4
fludarabine
3
durvalumab
3
Radiosurgery
3
Pemetrexed
3
Gemcitabine
3
Fluorouracil
3
Cyclophosphamide
3
Cisplatin
3
Cetuximab
3
Bortezomib
3
niraparib
2
motexafin gadolinium
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
aldesleukin
2
Tobacco Use Cessation Devices
2
Tetrahydrouridine
2
Taxes
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Tiragolumab
×
Genitourinary
×
Clear all
NCT05259319
2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1
Unknown
92 enrolled